YD Bio Limited Ordinary Shares(YDES)Earnings, Financials & Key Ratios
YDES•NASDAQ
$2.42
Price updated Jun 25, 2026
AboutBreeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.Show more
- Revenue$510K+45.8%
- EBITDA-$1M-18252.9%
- Net Income-$1M-10509.7%
- EPS (Diluted)-0.56-280100.0%
- Gross Margin30.44%-30.5%
- EBITDA Margin-265.93%-12490.7%
- Operating Margin-286.45%-10085.3%
- Net Margin-276.58%-7241.6%
- ROE-42.69%-17761.9%
YDES Price & Volume
YD Bio Limited Ordinary Shares (YDES) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Diagnostic Development Faces Critical Liquidity
Investment Thesis • Updated 2025Q2
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity insolvency risk
"YD Bio Limited remains in a high-risk, pre-commercial phase characterized by a complete lack of revenue and persistent operating losses. The company's financial stability is severely compromised by a rapid erosion of its equity base, which has shifted from a positive $3.0M in 2023Q4 to a negative $16.1M by 2025Q2. Investors should exercise extreme caution as the firm's aggressive capital allocation, including $7.4M in share repurchases during 2025Q1, appears fundamentally misaligned with its precarious cash position of only $6.3K."
Verdict Logic
the company's cash reserves have plummeted to a critical $6.3K, creating an imminent risk of insolvency that outweighs any potential upside from its diagnostic platform.
YDES Growth Metrics
YD Bio Limited Ordinary Shares (YDES) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-9.94%
5 Years-9.94%
3 Years-15.97%
Last Year-44.14%
Peers Comparison
Key metrics vs top competitors for YD Bio Limited Ordinary Shares (YDES)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.42 | $10.03M | -4.32 | 45.76% | -276.58% | -42.69% | — | |
| $1.93 | $628.48M | -6.23 | -30.65% | -146.01% | -0.11% | — | |
| $5.81 | $2.02B | -9.68 | 698.96% | -102.06% | -44.1% | — | |
| $18.52 | $2.05B | -11.58 | 15.33% | -39.29% | -24.32% | — | |
| $23.77 | $1.75B | -22.01 | 38.87% | -126.33% | -0.25% | — | |
| $0.96 | $926.9M | -31.12 | -6.62% | -0.77% | -0.22% | — |
Compare YDES vs Peers
YD Bio Limited Ordinary Shares (YDES) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when YDES posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
YDES Frequently Asked Questions
YD Bio Limited Ordinary Shares (YDES) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is YD Bio Limited Ordinary Shares's revenue?
YD Bio Limited Ordinary Shares (YDES) reported $0.5M in revenue for fiscal year 2024.
How fast is YD Bio Limited Ordinary Shares growing?
YD Bio Limited Ordinary Shares (YDES) grew revenue by 45.8% over the past year. This is strong growth.
Is YDES profitable?
YD Bio Limited Ordinary Shares (YDES) reported a net loss of $3.0M for fiscal year 2024.
Dividend & Returns
What is YDES's return on equity?
YD Bio Limited Ordinary Shares (YDES) has a return on equity (ROE) of -42.7%. Negative ROE indicates the company is unprofitable.
What is YD Bio Limited Ordinary Shares's free cash flow?
YD Bio Limited Ordinary Shares (YDES) had negative free cash flow of $1.2M in fiscal year 2024, likely due to heavy capital investments.